Other Events ·
BetterLife Pharma Inc. announced a strategic pivot to prioritize its lead asset, BETR-001, for migraine and primary…
BETRFBetterLife Pharma Inc.
BetterLife Pharma Inc. announced a strategic pivot to prioritize its lead asset, BETR-001, for migraine and primary headache disorders, leveraging a clinically validated serotonergic mechanism. The company initiated the final IND-enabling GLP toxicology study with Nucro-Technics Inc., having completed FDA pre-IND meetings and GMP scale-up manufacturing without LSD starting material, targeting an Investigational New Drug application filing in 1Q 2027. During July 2026, the company raised $352,500 through warrant exercises ($335,000) and stock option exercises ($17,500), while converting $76,361.65 in convertible debentures into units. The board appointed John W. LaRocca as a director and audit committee member, granting him 500,000 stock options at $0.19 per share. BetterLife Pharma Inc. is a biotechnology company engaged in the development of treatments for neurological disorders.